The ING1 Knockout SK-HEP-1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal population of SK-HEP-1 human hepatocellular carcinoma cells, offering a loss-of-function model for the ING1 tumor suppressor gene. This heterogeneous pool, generated through CRISPR/Cas9-mediated gene disruption, avoids the clonal bias of monoclonal lines, thereby reflecting a broader spectrum of knockout phenotypes. The product serves as a versatile tool for dissecting ING1-dependent processes including cell cycle regulation, apoptosis, and chromatin remodeling.
SK-HEP-1 cells, originally isolated from the ascites of a liver adenocarcinoma patient, are a well-established model for hepatocellular carcinoma research. They exhibit a hybrid phenotype with both epithelial and endothelial-like characteristics, making them valuable for studying angiogenesis, metastasis, and drug metabolism. Their robust in vitro growth and tumorigenic potential in xenograft assays provide a physiologically relevant context for examining tumor suppressor functions.
ING1 operates as a tumor suppressor by modulating p53-dependent and -independent pathways, interacting with p53 to enhance DNA damage-induced apoptosis and cell cycle arrest. It is regulated by upstream factors such as E2F1, MYC, and TGF-??, and associates with histone modifying complexes containing SAP30, mSin3a, HDAC1, and HDAC2. Downstream, ING1 influences expression of BAX, p21/CDKN1A, and MDM2, coordinating DNA repair, senescence, and apoptosis. CRISPR/Cas9 disruption abrogates these functions, impairing p53 signaling and altering histone acetylation.
In SK-HEP-1 cells, loss of ING1 disrupts p53-mediated DNA damage responses, promoting unchecked proliferation and reduced apoptosis. This polyclonal knockout model recapitulates key tumorigenic features of ING1-deficient liver cancers, enabling investigation of senescence evasion and dysregulated chromatin states. The hybrid epithelial-endothelial nature of SK-HEP-1 also facilitates studies on ING1??s role in angiogenesis and metastatic potential, particularly in the context of TGF-?? signaling crosstalk.
This ING1 knockout model supports a broad panel of assays, including western blotting, RT-qPCR, flow cytometry for cell cycle distribution, and Annexin V-based apoptosis detection. Proliferation, colony formation, migration, and invasion assays can delineate ING1-dependent growth and metastatic phenotypes. Drug sensitivity screens exploit the model to find compounds that reactivate p53 or exploit epigenetic vulnerabilities. ChIP-qPCR, co-immunoprecipitation of ING1 complexes, RNA-seq transcriptomics, and p53 luciferase reporter assays further extend its utility. For technical inquiries, contact Ascent Research.
